CA2305036A1 - Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4 - Google Patents

Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4 Download PDF

Info

Publication number
CA2305036A1
CA2305036A1 CA002305036A CA2305036A CA2305036A1 CA 2305036 A1 CA2305036 A1 CA 2305036A1 CA 002305036 A CA002305036 A CA 002305036A CA 2305036 A CA2305036 A CA 2305036A CA 2305036 A1 CA2305036 A1 CA 2305036A1
Authority
CA
Canada
Prior art keywords
cells
group
cxcr4
peptide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002305036A
Other languages
English (en)
Inventor
Ian Clark-Lewis
Johanne Cashman
Connie Eaves
Hassan Salari
Ahmed Merzouk
Geeta Saxena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of British Columbia
Chemokine Therapeutics Corp USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Chemokine Therapeutics Corp USA filed Critical University of British Columbia
Priority to CA002305036A priority Critical patent/CA2305036A1/fr
Priority to CA002335109A priority patent/CA2335109A1/fr
Priority to EP01925259A priority patent/EP1276493B1/fr
Priority to DE60106002T priority patent/DE60106002T2/de
Priority to CA002405907A priority patent/CA2405907A1/fr
Priority to BR0110049-1A priority patent/BR0110049A/pt
Priority to AT01925259T priority patent/ATE277628T1/de
Priority to AU2001252081A priority patent/AU2001252081B9/en
Priority to JP2001574131A priority patent/JP2003530355A/ja
Priority to US09/835,107 priority patent/US20020165123A1/en
Priority to PCT/CA2001/000540 priority patent/WO2001076615A2/fr
Priority to AU5208101A priority patent/AU5208101A/xx
Publication of CA2305036A1 publication Critical patent/CA2305036A1/fr
Priority to US10/086,177 priority patent/US7378098B2/en
Priority to US11/649,928 priority patent/US20070160574A1/en
Priority to JP2009023230A priority patent/JP2009143942A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002305036A 2000-04-12 2000-04-12 Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4 Abandoned CA2305036A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA002305036A CA2305036A1 (fr) 2000-04-12 2000-04-12 Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4
CA002335109A CA2335109A1 (fr) 2000-04-12 2001-02-23 Traitement de cellules hematopoietiques avec des agonistes du cxcr4
AU2001252081A AU2001252081B9 (en) 2000-04-12 2001-04-12 CXCR4 Agonist Treatment of Hematopoietic Cells
US09/835,107 US20020165123A1 (en) 2000-04-12 2001-04-12 CXCR4 agonist treatment of hemapoietic cells
CA002405907A CA2405907A1 (fr) 2000-04-12 2001-04-12 Traitement de cellules hematopoietiques utilisant des agonistes de cxcr4
BR0110049-1A BR0110049A (pt) 2000-04-12 2001-04-12 Agonista de cxcr4, uso de um agonista de cxcr4, e composição farmacêutica
AT01925259T ATE277628T1 (de) 2000-04-12 2001-04-12 Behandlung von hematopoietischen zellen mit cxcr4 agonisten
EP01925259A EP1276493B1 (fr) 2000-04-12 2001-04-12 Traitement de cellules hematopoietiques utilisant des agonistes de cxcr4
JP2001574131A JP2003530355A (ja) 2000-04-12 2001-04-12 造血細胞のｃｘｃｒ４アゴニスト処理
DE60106002T DE60106002T2 (de) 2000-04-12 2001-04-12 Behandlung von hämatopoetischen Zellen mit CXCR4 Agonisten
PCT/CA2001/000540 WO2001076615A2 (fr) 2000-04-12 2001-04-12 Traitement de cellules hematopoietiques utilisant des agonistes de cxcr4
AU5208101A AU5208101A (en) 2000-04-12 2001-04-12 Cxcr4 agonist treatment of hematopoietic cells
US10/086,177 US7378098B2 (en) 2000-04-12 2002-02-26 CXC chemokine receptor 4 agonist peptides
US11/649,928 US20070160574A1 (en) 2000-04-12 2007-01-04 Design of CXC chemokine analogs for the treatment of human diseases
JP2009023230A JP2009143942A (ja) 2000-04-12 2009-02-04 造血細胞のｃｘｃｒ４アゴニスト処理

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002305036A CA2305036A1 (fr) 2000-04-12 2000-04-12 Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4

Publications (1)

Publication Number Publication Date
CA2305036A1 true CA2305036A1 (fr) 2001-10-12

Family

ID=4165864

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002305036A Abandoned CA2305036A1 (fr) 2000-04-12 2000-04-12 Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4

Country Status (1)

Country Link
CA (1) CA2305036A1 (fr)

Similar Documents

Publication Publication Date Title
US6946445B1 (en) Therapeutic chemokine receptor antagonists
US7354899B2 (en) Methods of treating autoimmune diseases comprising administering CXCR4 antagonists
US7435718B2 (en) CXCR4 antagonist treatment of hematopoietic cells
AU2001258110B2 (en) Cxcr4 antagonist treatment of hematopoietic cells
AU2001252081B2 (en) Cxcr4 agonist treatment of hematopoietic cells
WO2000009152A1 (fr) Antagonistes therapeutiques du recepteur de la chimiokine
AU2001258110A1 (en) Cxcr4 antagonist treatment of hematopoietic cells
US7378098B2 (en) CXC chemokine receptor 4 agonist peptides
AU2001252081A1 (en) CXCR4 Agonist Treatment of Hematopoietic Cells
CA2305036A1 (fr) Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4
AU2005201244B2 (en) CXCR4 agonist treatment of hematopoietic cells
CA2322764A1 (fr) Antagonistes therapeutiques du recepteur de chemokine
CA2405907A1 (fr) Traitement de cellules hematopoietiques utilisant des agonistes de cxcr4
CA2408319A1 (fr) Traitement de cellules hematopoietiques base sur des antagonistes du cxcr4
JP2000186045A (ja) 骨吸収抑制剤
CA2307705A1 (fr) Modulation de l'inflammation a l'aide de produits du type protease
WO2001090361A2 (fr) Modulation des effets de protease sur des substrats de chimiokines

Legal Events

Date Code Title Description
FZDE Dead